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In glioblastoma (GBM), heterogeneous expression of amplified and mutated epidermal growth factor receptor
(EGFR) presents a substantial challenge for the effective use of EGFR-directed therapeutics. Here we demonstrate
that heterogeneous expression of the wild-type receptor and its constitutively active mutant form, EGFRvIII, limits
sensitivity to these therapies through an interclonal communication mechanism mediated by interleukin-6 (IL-6)
cytokine secreted from EGFRvIII-positive tumor cells. IL-6 activates a NF-κB signaling axis in a paracrine and au-
tocrinemanner, leading to bromodomain protein 4 (BRD4)-dependent expression of the prosurvival protein survivin
(BIRC5) and attenuation of sensitivity to EGFR tyrosine kinase inhibitors (TKIs). NF-κB and survivin are coordi-
nately up-regulated in GBM patient tumors, and functional inhibition of either protein or BRD4 in in vitro and in
vivo models restores sensitivity to EGFR TKIs. These results provide a rationale for improving anti-EGFR thera-
peutic efficacy through pharmacological uncoupling of a convergence point of NF-κB-mediated survival that is le-
veraged by an interclonal circuitry mechanism established by intratumoral mutational heterogeneity.
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Glioblastoma (GBM) is the most deadly form of cancer of
the human central nervous system, with a median sur-
vival of 12–15mo and a 5-yr survival rate of <5% (Clough-
esy et al. 2014). Standard of care treatment includes
maximal surgical resection followed by radiotherapy con-
comitant with adjuvant temozolomide (Stupp et al. 2005).
The aggressive nature of GBM is reflected by its invasion
and disruption of normal brain parenchyma, intratumoral
heterogeneity, and resistance to treatment. This heteroge-
neity presents phenotypically as mixed cytological sub-
types within the tumor, genotypically as mixed
mutations and gene amplifications, and transcriptionally
as regional differences in gene expression. As a result,
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these multiple and spatially distinct heterotypic popula-
tions within a GBMmake any lesion- or pathway-specific
therapy less effective (Verhaak et al. 2010; Brennan et al.
2013; Patel et al. 2014; Louis et al. 2016). While con-
siderable effort has been placed on understanding the
interactions between heterotypic tumor cells and the sur-
rounding normal microenvironment, much less is known
about the interactions between and among heterogeneous
tumor cells within these neoplasms and how these inter-
actions might influence response to therapy.
Amplification and/ormutation of the epidermal growth
factor receptor (EGFR) occurs in nearly 60% of GBM
(Brennan et al. 2013), thus representing a potentially valu-
able therapeutic target. While inhibition of EGFR has
proven efficacious in other cancer types such as lung can-
cer, the response of GBM patients to anti-EGFR therapy
has been disappointing (Reardon et al. 2014). The hetero-
geneity of EGFR expression has a profound impact on
GBM biology. Wild-type EGFR (wtEGFR) and the con-
stitutively active mutant form of the receptor (EGFRvIII)
establish a paracrine-mediated interclonal cross-talk
circuitry in which minor populations of EGFRvIII-ex-
pressing cells within the tumor potentiate the fitness of
the wtEGFR-expressing cells through the secretion of in-
terleukin-6 (IL-6) (Inda et al. 2010). Indeed, high expres-
sion levels of IL-6 have been linked to poor prognosis,
chemoresistance, and cancer progression inGBM and oth-
er cancer types (Tchirkov et al. 2007; Wang et al. 2009;
Charles et al. 2011; Bent et al. 2016). Additionally, EGFR-
vIII, regardless of its constitutive activity, is a substrate for
wtEGFR, leading to STAT signaling and tumorigenicity in
a cell-intrinsic fashion (Fan et al. 2013).
While these heterotypic EGFR interactions promote en-
hanced tumor growth, the consequences of this genetic
heterogeneity on anti-EGFR therapy in GBM have not
been adequately investigated. Here we used in vitro and
in vivo analysis of human and murine GBM cell lines,
patient-derived xenograft (PDX)models, and clinical spec-
imens fromGBMpatients todescribeanactiveattenuation
in sensitivity to EGFR tyrosine kinase inhibitors (TKIs)
that is mediated by EGFRvIII-driven production of IL-6. In
turn, activation of the IL-6 common receptor gp130, ex-
pressed on wtEGFR cells, promoted NF-κB activation and
subsequent expression of a prosurvival gene target,
BIRC5 (referred to here with the protein name survivin).
This signaling axis could be efficiently uncoupled by the
epigenetic regulator bromodomain and extraterminal
(BET) protein family inhibitor JQ1, leading to inhibition
of survivin expression and restoration of sensitivity to
anti-EGFR therapy. These results suggest that, in addition
to cell-intrinsicmechanisms (Lynch et al. 2004;Mellingh-
off et al. 2005; Diaz et al. 2012; Nathanson et al. 2014;
Wykoskyetal. 2015), attenuationof response to these ther-
apies can also occur through extrinsic cues fostered by
interclonal tumor cell communication. Understanding
heterogeneous tumor cell interactions, as exemplified by
the EGFR mutational landscape found in GBM (Brennan
et al. 2013), will better inform strategies to overcome
therapy resistance commonly encountered for this
tumor type.
Results
EGFRvIII-specific secreted factors promote resistance
to EGFR kinase inhibitors in vitro and in vivo
The EGFRvIII-linked secretome promotes wtEGFR phos-
phorylation (Supplemental Fig. S1A), the proliferation of
wtEGFR+ cells, and the maintenance of wtEGFR/EGFR-
vIII heterogeneity in GBM (Inda et al. 2010). We sought
to determine whether this secretome might also possess
the ability to confer resistance to EGFR TKIs. Type I
EGFR TKIs (gefitinib and erlotinib), which bind to the ac-
tive conformation of EGFR, and type II EGFR TKIs (e.g.,
lapatinib), which bind to the inactive state of the receptor
(Park and Lemmon 2012), were tested for their ability to
inhibit soft agar colony growth of U87MG glioma cells
expressing wtEGFR (Inda et al. 2010) incubated with con-
ditioned medium (CM) derived from U87MG cells ex-
pressing EGFRvIII CM (vIII-CM) or parental cell CM
(Ctrl-CM) as a control. As shown in Figure 1, Ctrl-CM
showed significantly reduced wtEGFR colony formation
in the presence of EGFR TKIs; however, vIII-CM neutral-
ized this effect (Fig. 1A) despite the inhibition of EGFR
activation (Supplemental Fig. S1A). Similar results were
also observed in two-dimensional (2D) cell growth assays
(Supplemental Fig. S1B) and were further substantiated by
a complementary series of experiments using primary
astrocytes derived from Ink4a/Arf−/− mice that overex-
press wtEGFR (mAstr–Ink4a/Arf−/−-wtEGFR) (Fig. 1B;
Supplemental Fig. S1A; Inda et al. 2010). We next evaluat-
ed whether the observed TKI resistance phenotype was
due to modulation of apoptosis induction. By assessing
both caspase 3/7 activation and annexin V cell surface
expression, we determined that vIII-CM potently inhibit-
ed cell death induced by EGFR TKIs (Fig. 1C,D; Supple-
mental Fig. S1C). These results show that EGFRvIII
paracrine factors promote resistance to anti-EGFR thera-
pies in vitro irrespective of the source of the CM, as
both human and murine cells show similar effects.
We then attempted to model wtEGFR/EGFRvIII recep-
tor cross-talk and anti-EGFR therapy resistance in in
vivo experiments using a system inwhichwe could specif-
ically target EGFRvIII in engrafted mixed tumors. Here,
U87MG cells were stably transduced to express an ana-
log-sensitive allele of EGFRvIII (EGFRvIIIas3), which has
been shown previously to be inhibited for kinase activa-
tion by compound 1-NA-PP1 (Fan et al. 2013). After con-
firming that 1-NA-PP1 was able to cross the blood–brain
barrier, down-regulate EGFRvIII-associated signaling,
and impair IL-6 secretion specifically in EGFRvIIIas3-
expressing cells (Supplemental Fig. S2A–D), an equal
mixture of wtEGFR and EGFRvIIIas3 tumor cells was
orthotopically engrafted into the brains of immunocom-
promised mice (Fig. 1E). Seven days after injection, the
mice were treated with 10 mg/kg 1-NA-PP1 or a control
solution for the next 7 d with the addition of 200 mg/kg
lapatinib throughout this regimen. Upon sacrifice, the
mouse brains were dissected, and isolated tumor cells
were stained for cleaved caspase 3 and TUNEL staining
(Fig. 1F; Supplemental Fig. S2E), which showed that
cotreatment with 1-NA-PP1 and lapatinib resulted in an
NF-κB attenuates EGFR TKI sensitivity in GBM
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increase in apoptosis detection inwtEGFR cells compared
with lapatinib or 1-NA-PP1 treatment alone. Taken to-
gether, these results show that EGFRvIII exerts protective
cell-extrinsic effects on neighboring wtEGFR+ cells in
vivo, which attenuate sensitivity to EGFR TKI treatment.
IL-6 mediates resistance to EGFR TKIs in GBM
IL-6 has been reported to have a prominent role in promot-
ing chemoresistance in GBM and other types of cancers
(Tchirkov et al. 2007; Wang et al. 2009; Lee et al. 2014;
Bent et al. 2016). Since EGFRvIII+ cells and tumors have
been shown to secrete elevated levels of IL-6, which
supports wtEGFR ligand-independent phosphorylation
through gp130 activation (Inda et al. 2010), we evaluated
a potential role of this EGFRvIII-prompted paracrine fac-
tor as an anti-apoptotic effector against EGFR TKIs.
shRNAs targeting IL-6 were used to down-regulate its ex-
pression in U87EGFRvIII cells (Supplemental Fig. S3A),
and CM from cells with reduced cytokine levels was ap-
plied towtEGFR+ cells in the presence of EGFRTKIs. Sub-
sequently, cell viability and cell death were measured by
soft agar colony formation and caspase activation, respec-
tively. As shown in Figure 2, CM from IL-6 knockdown
cells was deficient in protecting from TKI-induced cell
death when compared with CM from control shRNA cells
Figure 1. EGFRvIII-secretedmolecules exert anti-apoptotic action. (A,B) Soft agar colony formation assay quantification of U87wtEGFR
cells treated with control medium obtained from parental U87MG cells (Ctrl-CM) or EGFRvIII cells (vIII-CM) in the presence of EGFR
TKIs (A) and mAstr–Ink4/Arf−/−-wtEGFR cells treated with control medium obtained from parental mAstr–Ink4/Arf−/− cells or
mAstr–Ink4/Arf−/−-vIII in the presence of EGFRTKIs (B). Colony numberwas determined fromnine fields for each condition. (V) Vehicle;
(G) gefitinib; (E) erlotinib; (L) lapatinib. (C,D) Caspase 3/7 activation assay of U87wtEGFR cells treated with control medium obtained
from parental U87MG cells (Ctrl-CM) or EGFRvIII cells (vIII-CM) in the presence of EGFR TKIs (C ) and mAstr-Ink4/Arf−/− wtEGFR cells
treated with control medium obtained from parental mAstr–Ink4/Arf−/− cells (Ctrl-CM) or EGFRvIII cells (vIII-CM) in the presence of
EGFR TKIs (D). Luminescence as relative light unit (RLU) intensity with blank subtracted and average values with standard deviations
is shown. Percentage over control is reported. One-way ANOVA and two-tailed Student’s t-test were used to compare samples. (∗∗) P <
0.001; (ns) nonsignificant. (E) Intratumoral localization of EGFRvIIIas3 cells labeled with TurboFP635 (Alexa fluor 647) and U87wtEGFR
cells labeled with iRFP720 (Alexa fluor 555). Bars, 20 µm. (F ) Apoptotic wtEGFR cells in intracranial mixed tumors were identified by
gating on EGFR antibody-stained cells (not shown) followed by detection of cleaved caspase 3. n = 4. Data are represented as mean ± SD.
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(Fig. 2A,B). In contrast, overexpression of IL-6 in U87 pa-
rental cells resulted in CM with an increased ability to
protect from EGFR TKI-mediated apoptosis (Supplemen-
tal Fig. S3B–D). To further confirm the role of IL-6 in pro-
moting attenuated sensitivity to these inhibitors,
U87wtEGFR cells were treated with vIII-CM in the pres-
ence of gefitinib with the addition of neutralizing antibod-
ies for IL-6 and LIF, which are enriched in vIII-CM (Inda
et al. 2010). Cytokine signaling neutralization resulted
in an increase in apoptosis induction (as measured by cas-
pase 3/7 activation and TUNEL assay) and a decrease in
proliferation. Additionally, blocking the IL-6 and LIF cor-
eceptor gp130, expressed on wtEGFR cells, produced sim-
ilar results (Fig. 2C; Supplemental Fig. S3E). To validate
the role of IL-6 in mediating resistance to EGFR TKIs,
we tested PDX models GSC11, GSC23, TS543, and
TS576, engineered to overexpress wtEGFR (Supplemental
Fig. S3F). These PDX models were exposed to EGFR TKIs
in the presence or absence of recombinant IL-6, and prolif-
eration and apoptosis were measured as above (Fig. 2D,E).
Neutralization of gp130 also resulted in an increased re-
sponse to EGFR inhibition in the PDX model GSC23,
Figure 2. Role of IL-6 in resistance to anti-EGFR therapy. (A) Soft agar colony formation assay quantification of U87wtEGFR cells treated
with CM obtained from EGFRvIII cells transduced with control shRNA (shGFP-vIII-CM) or shRNAs against IL-6 (shIL6#1-vIII-CM or
shIL6#2-vIII-CM) in the presence or absence of EGFR TKIs. (B) Caspase activation assay of U87wtEGFR treated with the same conditions
as inA. (C ) Caspase activation assay inU87wtEGFRcells in the presence of human gp130-neutralizing or IL-6/LIF-neutralizing antibodies.
(D,E) Cell proliferation analysis by WST-1 assay (indicated as proliferation index) and caspase activation assay in PDX models. Data are
represented as mean ± SD.
NF-κB attenuates EGFR TKI sensitivity in GBM
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which expresses high levels of endogenous IL-6 (Supple-
mental Fig. S3G–I). Since LIF also acts through the
gp130 coreceptor and is secreted by EGFRvIII cells, we
tested LIF for its ability to attenuate EGFR TKI sensitiv-
ity. GSC11wtEGFR, TS543wtEGFR, and TS576wtEGFR
were stimulated with recombinant LIF and treated with
EGFR TKIs followed by assessment of cell proliferation
and caspase activation. Addition of LIF to the culture me-
dium induced resistance to EGFR TKIs in PDX models
(Supplemental Fig. S4A,B). Altogether, these experiments
identify IL-6/gp130 as potent mediators of anti-apoptotic
signaling leading to attenuation of EGFR TKI-induced
cell death in GBM.
Survivin plays a major role in resistance to EGFR TKIs
To identify the genes responsible for EGFR TKI resis-
tance in wtEGFR+ cells induced by EGFRvIII-mediated
soluble factors, a real-time quantitative PCR (qPCR)
screening of apoptosis-related genes was performed on
U87wtEGFR+ cells treated with Ctrl-CM or vIII-CM.
BIRC3, BIRC5, and TNFSF10 were among the genes spe-
cifically altered for expression by vIII-CM treatment
(Fig. 3A). The Cancer Genome Atlas (TCGA) microarray
analysis showed that the anti-apoptotic protein BIRC5, re-
ferred to here as survivin, is up-regulated in GBM versus
normal brains (Fig. 3B). These results were also confirmed
by real-time qPCR using specific primers for survivin
cDNA and Western blotting analysis in wtEGFR+ cells
treated with vIII-CM (Fig. 3C). Similar results were ob-
tained in U178 glioma cells transduced with wtEGFR
and treated with vIII-CM (Supplemental Fig. S5A). To
identify apoptosis-related genes directly regulated by IL-
6, a real-time qPCR array consisting of these genes was
performed also on TS576wtEGFR PDX cells treated with
this cytokine, which confirmed that survivin was similar-
ly up-regulated in this model (Supplemental Fig. S5B). Ex-
posure of U87wtEGFR cells or PDX models (GSC11,
TS543, or TS576 overexpressing wtEGFR) to recombinant
IL-6 also induced survivin, while inhibition of IL-6 signal-
ing by gp130-neutralizing antibody in GSC23wtEGFR
cells resulted in a reduction in its expression (Fig. 3D).
To validate the role of survivin in protecting the cells
from EGFR TKI-induced apoptosis, its expression was
knocked down inU87wtEGFRcells by shRNAs,which re-
sulted in sensitization to gefitinib treatment (Fig. 3E). The
specificity of survivin knockdown was confirmed by
reconstituting survivin using knockdown-resistant ex-
pression constructs (Supplemental Fig. S5C). Moreover,
survivin knockdown was performed in PDX models
expressing exogenous levels of wtEGFR or endogenous
levels of EGFRvIII, which were similarly sensitized to
EGFR TKI treatment (Supplemental Figs. S5D,E, S6A–
C). To confirm these results in vivo, admixing experi-
mentswere performed usingU87wtEGFRcells expressing
control or survivin shRNAs orthotopically engrafted in
the brains of immunocompromised mice at a ratio of
90%U87wtEGFR to 10% EGFRvIII (Inda et al. 2010). Sev-
en days after the injection, mice were treated with 200
mg/kg lapatinib for an additional 7 d. Upon sacrifice, their
brains were dissected, and tumors were dissociated.
wtEGFR cells were identified by specific EGFR antibody
staining and stained for cleaved caspase 3 and TUNEL.
Mixed tumors with U87wtEGFR survivin knockdown
cells treated with lapatinib had an increase in apoptotic
index when compared with lapatinib treatment of shRNA
control mice (Fig. 3F; Supplemental Fig. S6D). In contrast,
exogenous survivin expression in wtEGFR+ cells protect-
ed the cells from EGFR TKI-induced apoptosis in vitro
(Supplemental Fig. S6E). Mechanistically, vIII-CM in-
creased survivin cytosolic localization (Fig. 3G), which
is associated with a prosurvival phenotype (Chan et al.
2010). Additionally, we detected interaction with XIAP
and Smac/DIABLO (Fig. 3H), particularly when survivin
was localized in the cytosol (Supplemental Fig. S7A), but
no association was observed with caspase 3, caspase 6,
caspase 7, caspase 8, or caspase 9 (data not shown). Direct
interaction between XIAP and survivin enhances XIAP
caspase inhibition. Furthermore, interaction between
Smac/DIABLO and survivin neutralizes Smac/DIABLO
proapoptotic functions. Altogether, these findings sup-
port a role for survivin as a prosurvival mediator induced
by vIII-CM in cancer cell types within the tumormicroen-
vironment (Altieri 2008; Chan et al. 2010).
Because this phenotype was mediated by secreted fac-
tors, we investigated the possibility that these factors
might also act in an autocrine fashion. U87 parental,
EGFRvIII, and wtEGFR cells were serum-starved for 24
h, and survivin expression was evaluated by real-time
qPCR and Western blotting, which showed that survivin
was highly expressed in EGFRvIII cells compared with
their parental or wtEGFR+ counterparts in a gp130-depen-
dent fashion (Supplemental Fig. S7B). Similar results were
obtained in U178MG and U373MG cells (Supplemental
Fig. S7B) as well as U373MG cells expressing a tetracy-
cline-regulated EGFRvIII construct (Wykosky et al.
2015) (Supplemental Fig. S7C). To determinewhether sur-
vivin has a role in acquired resistance to EGFR TKIs in
GBM, we used an establishedmodel of induced resistance
to EGFRTKIs (Wykosky et al. 2015). Here, gefitinib-sensi-
tive and gefitinib-resistant primary Ink4a/Arf−/−-EGFR-
vIII mouse astrocytes were screened using a real-time
qPCR array of apoptosis-related genes, which revealed
that survivin was among the most up-regulated genes in
the resistant state (Supplemental Fig. S7D). Survivin up-
regulation in resistant astrocytes was confirmed by real-
time qPCR in additional Ink4a/Arf
−/−
-EGFRvIII gefitinib-
resistant primary astrocyte cell lines (Supplemental Fig.
S7E). Overall, these results suggest that survivin expres-
sion is regulated by EGFRvIII in an autocrine and para-
crine fashion and is a mediator of EGFR TKI resistance
in GBM.
NF-κB regulates survivin expression in GBM
To determine the mechanism by which IL-6 is mediating
survivin expression, we performed a bioinformatic analy-
sis of transcription factor response elements in the survi-
vin promoter, which revealed putative binding sites for
STAT3 and NF-κB (Supplemental Fig. S8A). As IL-6 is
Zanca et al.
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known to mediate STAT3 activation (Wang et al. 2009),
we first assessed whether this transcription factor was
linked to survivin expression; however, an analysis of
TCGAGBM transcriptomes failed to show an association
between a STAT3 signature and survivin (BIRC5) expres-
sion (Supplemental Fig. S8B). Moreover, modulation of
STAT3 activity using a dominant-negative mutant or a
constitutively active version of STAT3 did not alter
Figure 3. Identification of survivin as an EGFRvIII-induced apoptosis inhibitor that attenuates EGFRTKI sensitivity inwtEGFRcells. (A)
Real-time PCR screening of apoptosis-related genes inU87wtEGFRcells treatedwith vIII-CMversus control. (B) Microarray analysis from
TCGA GBM samples for BIRC3, BIRC5, and TNFSF10. (C ) vIII-CM up-regulates survivin expression in wtEGFR cells as evaluated by
Western blotting analysis (right) and real-time PCR (left). (D) Real-time PCR analysis of survivin expression upon IL-6 treatment or
gp130-neutralizing antibody in GBM PDX cell lines. (E) shRNA-mediated down-regulation of survivin expression (Western; top) and cas-
pase activation assay (bottom) in cells treatedwith 5 µMgefitinib. (F ) EGFRvIII cells andwtEGFRcells transducedwith shGFP, shsurvivin
#1, or shsurvivin #2 were engrafted intracranially at 10%:90% ratio, respectively. Following tumor establishment, the mice were treated
with 200mg/kg lapatinib, and apoptosis wasmeasured in wtEGFR cells using FACS analysis for cleaved caspase 3 staining. n = 4mice for
each condition. (G) Immunofluorescence staining for survivin (Alexa fluor 594) in U87wtEGFR cells in the presence of Ctrl-CM or vIII-
CM. (H) Immunoprecipitation analysis of survivin interactors Smac/DIABLO and XIAP (top) and total lysates (bottom). Bars, 10 µm. Data
are represented as mean ± SD.
NF-κB attenuates EGFR TKI sensitivity in GBM
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survivin expression in U87EGFRvIII cells (Supplemental
Fig. S8C). In contrast, a similar analysis of GBMs with
an EGFR-associated classical subgroup signature (Brennan
et al. 2013) showed significant expression correlation
between BIRC5 and the NF-κB subunit RelA (p65) tran-
scription factor (Fig. 4A). Confirming a direct role for
Figure 4. NF-κB controls survivin expression in GBM. (A) TCGAGBM transcriptomal profile association between survivin and RelA in
the classical GBM subgroup. (B) ChIP-PCR analysis of p65 enrichment on the survivin promoter in U87wtEGFR cells (left) and
TS576wtEGFR cells (right). The genomic region examined is located at −226 from the transcriptional start site. (C ) Survivin promoter ac-
tivity upon vIII-CM treatment. IKBSR- or p65-binding site deletions inhibited the activity of the promoter upon vIII-CM treatment. (D)
Western blot analysis of survivin expression inU87wtEGFR transducedwith IKBSR and treatedwith vIII-CM. (E) NF-κB response element
reporter assay of U87wtEGFR with the indicated conditions. (F ) Sequential ChIP analysis for bromodomain protein 4 (BRD4) and p65 on
survivin promoter. (Left) The results for p65 (first antibody) and BRD4 (second antibody) ChIP analysis is shown. (Right) The results for
BRD4 (first antibody) and p65 (second antibody) ChIP analysis is shown. (G) ChIP-PCR analysis of BRD4 enrichment on the survivin pro-
moter. (H) NF-κB response element reporter assay. (I ) Survivin promoter activation. (J) Survivin expression in the presence of 0.5 µM BET
bromodomain inhibitors for 48h. (K ) JQ1 (0.5 µM) sensitizes cells to gefitinib-induced apoptosis. (L) JQ1 (0.5 µM) in combinationwith 2µM
EGFRTKIs reducedcell proliferationand inducedapoptosis inEGFRvIII-positivePDXcell lines invitro.Data are representedasmean ± SD.
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NF-κB in survivin expression, the three potential NF-κB-
binding sites in its promoter region were tested by chro-
matin immunoprecipitation (ChIP) combined with PCR
(ChIP-PCR), which showed enrichment for p65 binding
upon vIII-CM treatment of U87wtEGFR cells and upon
IL-6 treatment of the TS576wtEGFR PDX model when
compared with the untreated control (Fig. 4B; Supplemen-
tal Fig. S8D,E). In conjunction with this result, a survivin
promoter reporter construct (−1000 base pairs [bp] to +1)
containing these NF-κB response elements showed that
promoter activitywas stimulated upon vIII-CM treatment
and that its activity was efficiently inhibited by IκB super-
repressor (IκB-SR) (Friedmann-Morvinski et al. 2016) or
deletions of the three NF-κB-binding sites (Fig. 4C). We
validated the role of NF-κB in regulating survivin expres-
sion by transiently expressing IκB-SR in U87wtEGFR in
the presence of vIII-CM, which showed that IκB-SR po-
tently represses survivin expression (Fig. 4D). To confirm
NF-κB activation upon vIII-CM treatment, wtEGFR+ cells
were transduced with an NF-κB reporter vector (NF-κB-
RE) in the presence or absence of IκB-SR and treated
with vIII-CM. Reporter activity showed thatNF-κB activa-
tion was inhibited by IκB-SR or by neutralizing IL-6/gp130
signaling (Fig. 4E). In total, these results illustrate that
vIII-CM potently up-regulates NF-κB activity, which in
turn promotes survivin expression.
The NF-κB/survivin axis represents a potential tar-
getable pathway for combinatorial therapy together
with EGFR TKIs. It was shown recently in an atherogenic
inflammatory response that bromodomain protein 4
(BRD4) can orchestrate NF-κB-dependent superenhancer
formation through direct binding to NF-κB (Brown et al.
2014), which we similarly confirmed also occurs at the
survivin promoter upon vIII-CM treatment (Fig. 4F). NF-
κB signaling inhibition by IκB-SR or neutralizing gp130
in the presence of vIII-CM treatment reduced BRD4 re-
cruitment on the survivin promoter (Fig. 4G). Since BET
bromodomain inhibitors can inhibit BRD4 and impede
other transcription factors coactivated by BRD4, such as
NF-κB or MYC, we determined whether this possibility
also occurred in our model by testing three such in-
hibitors: JQ1, I-BET-151, and I-BET-762 (Shi and Vakoc
2014). Inhibitor pretreatment of wtEGFR+ cells prior to
vIII-CM and EGFRTKI addition reducedNF-κB activation
(as measured by NF-κB and survivin reporter assays) (Fig.
4H,I), down-regulated survivin expression in U87wtEGFR
and PDX cell lines (Fig. 4J; Supplemental Fig. S8F), and
strongly induced apoptosis (Fig. 4K) without affecting p65
deposition on the survivin promoter (Supplemental Fig.
S8G). Furthermore, direct down-regulation of BRD4 by
shRNA did not interferewith p65 deposition on the survi-
vin promoter (Supplemental Fig. S8H). Additionally, we
confirmed that the direct stimulation of TS576wtEGFR
cells with IL-6 induced BRD4 recruitment to the survivin
promoter (Supplemental Fig. S9A). Next, we evaluated
the effects of the combined treatment of EGFR TKIs and
JQ1 in PDX models GBM6, GBM39, and HK296, which
express endogenous levels of EGFRvIII. The combined
treatment similarly resulted in a reduction of prolifera-
tion as well as induction of apoptosis (Fig. 4L), while sur-
vivin overexpression was sufficient to rescue GBM cells
from JQ1-induced apoptosis (Supplemental Fig. S10A).
GSC11wtEGFR, TS543wtEGFR, and TS576wtEGFR also
showed a strong response to a lapatinib plus JQ1 combina-
tion in the presence of IL-6 (Supplemental Fig. S10B). We
also tested other pharmacological inhibitors capable of
blocking the NF-κB/survivin axis. Among the intracellu-
lar pathways that regulate NF-κB activity, we tested the
PI3K/mTORC2 pathway for its possible role in vIII-CM-
mediated NF-κB activation (Tanaka et al. 2011). Here,
PI-103 and PP242 inhibitors reduced NF-κB activation
and survivin expression and, in combination with gefiti-
nib, increased apoptosis in wtEGFR cells (Supplemental
Fig. S11A–D). We also tested NF-κB pathway inhibitor
MLN120B (IKKβ) (Cahill et al. 2016) in combination
with gefitinib, and similar results were obtained (Supple-
mental Fig. S11A–D). It has been described previously
that BET bromodomain inhibitors also inhibit MYC acti-
vation (Shi and Vakoc 2014). To determine whether this
oncogene was playing a role in our model, we transduced
U87wtEGFR cells with a constitutively active MYC
(T58A) (Hemann et al. 2005), which failed to increase
survivin expression (Supplemental Fig. S11E). Survivin ex-
pression depended on BRD4 because shRNAdown-regula-
tion of BRD4 in U87EGFRvIII cells (Liu et al. 2015)
resulted in reduced survivin levels (Supplemental Fig.
S11E). Moreover, we evaluated caspase activation in
U87wtEGFR cells transduced with IκB-SR and then treat-
ed with JQ1 in the presence of vIII-CM, which did not fur-
ther increase induction of apoptosis when compared with
IκB-SR alone, indicating that inhibition of NF-κB is pri-
marily responsible for regulating apoptosis in response
to JQ1 (Supplemental Fig. S11F). Since BET bromodomain
inhibitors demonstrated the highest potential in inducing
apoptosis when combined with EGFR inhibitors, we de-
cided to test the combination of these drugs in vivo using
the PDX models GBM39, GBM6, and HK296 (Nathanson
et al. 2014). PDX cells expressing the near-infrared fluores-
cent protein iRFP720 (Supplemental Fig. S11G; Shcherba-
kova and Verkhusha 2013) were orthotopically engrafted
into the brains of nude mice. Seven days after the injec-
tion, the mice were treated five times per week with lapa-
tinib and/or JQ1, and tumor burden was monitored by
fluorescence molecular tomography (FMT) until the ap-
pearance of neurological symptoms, at which time the
mice were euthanized. As shown in Figure 5, JQ1 exhibit-
ed brain penetrance (Fig. 5A), and combined treatment
was able to reduce the tumor size and prolong the lives
of the animals significantly when compared with untreat-
ed or single-treatment groups (Fig. 5B–E). We also tested
the possibility of BET proteins as a potential target to
sensitize GBMs to inhibition of other receptor tyrosine
kinases. To this aim, we used GBM8, a PDX with extra-
chromosomal DNA (ecDNA) PDGFRα overexpression
(Supplemental Fig. S12A,B). Cells were treated with cren-
olanib (a PDGFRα/β inhibitor) (Supplemental Fig. S12C)
and JQ1, and cell proliferation and apoptosis were mea-
sured (Supplemental Fig. S12D,E). Similar to our results
above, JQ1 also sensitized GBM8 cells to crenolanib-in-
duced apoptosis.
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EGFRvIII mediates IL-6 secretion through AKT pathway
activation
Our previous studies have shown that EGFRvIII prompted
secretion of the protumorigenic and angiogenic cytokines
IL-6 and IL-8 (Inda et al. 2010). To identify candidate path-
ways regulating cytokine production, in particular IL-6,
we screened a series of EGFRvIII alleles in which tyrosine
phosphorylation target residues within the C-terminal
tail had been mutated singly or in combinations to phe-
nylalanine (DY mutants series) (Fig. 6A). Such mutations
ablate particular pathways of signal transduction used by
the receptor (Huang et al. 2007). CM from U87MG cells
expressing these various DY mutants was assessed using
a Bio-Plex multiplex system for IL-6 as well as LIF, IL-8,
GROα, MCP-1, and G-CSF secretion (Fig. 6B; Supplemen-
tal Fig. S13A; Inda et al. 2010). Mutant receptors DY3,
DY6, and DY8 showed consistent reduction in IL-6 secre-
tion, which was confirmed by ELISA (Supplemental Fig.
S13B). To determine which intracellular pathway is re-
sponsible for cytokine production and specifically inhibit-
ed in the DY3, DY6, and DY8mutants (Supplemental Fig.
S13C), we used a Bio-Plex phosphoprotein assay platform
to screen for possible candidates. Serum-starved cells har-
vested for phosphoprotein analysis showed that AKT acti-
vation was ablated in all DYmutants; meanwhile, STAT3
activation was not affected by such mutations (Supple-
mental Fig. S13D). These results, confirmed by Western
Figure 5. JQ1 sensitizes GBM cells to
EGFR TKI-induced apoptosis, and the com-
binatorial treatment inhibits tumor growth
and prolongs the survival of mice bearing
orthotopic PDX models. (A) JQ1 levels in
mouse plasma and brains at different time
points after oral dosing as determined by
liquid chromatography/mass spectrometry
(LC/MS). FMT analysis of GBM39 (B),
GBM6 (C ), or HK296 (D) orthotopic xeno-
graft tumor burden quantification and sur-
vival curves. n = 8. (E) Average survival
(days) of nude mice bearing intracranial tu-
mors and treated with vehicle (V), lapatinib
(L), JQ1 (J), or a combination of both lapati-
nib and JQ1 (L + J). Data are represented as
mean ± SD.
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blotting analysis (Fig. 6C), are consistent with the Y1068
mutation shared among DY3, DY6, and DY8, which is a
phosphotyrosine site in EGFR linked to AKT activation
(Huang et al. 2007). Because NF-κB has been shown to reg-
ulate IL-6 production (Iliopoulos et al. 2009), we evaluated
the NF-κB activation status in the EGFRvIII-DY mutants
using a NF-κB reporter construct as used in Figure 4,
which showed that NF-κB activity was reduced by the
DY3, DY6, andDY8mutants (Fig. 6D). Additionally, since
AKT activity can activate NF-κB (Dan et al. 2008), we
evaluated the effects of inhibiting the AKT pathway on
NF-κB activation. Pharmacological AKT inhibition result-
ed in a down-regulation of reporter activity for bothNF-κB
and the IL-6 promoter (Fig. 6E). Dependency of IL-6 pro-
duction on NF-κB activity was further confirmed using
IκB-SR (Supplemental Fig. S14A), and a similar depend-
ency on BRD4 was measured by real-time PCR after JQ1
treatment of U87EGFRvIII cells (Supplemental Fig.
S14B). We further validated NF-κB activation dependency
on AKT activity using a dominant-negative (DN) AKT,
which inhibited NF-κB (Supplemental Fig. S14C) and a
constitutively active form of AKT, which in turn activat-
ed NF-κB (Supplemental Fig. S14D). Finally, we evaluated
the dependency of IL-6 production on AKT in GBM39,
GBM6, and HK296 PDX models treated with AKT phar-
macological inhibitors or transduced with IκB-SR (Fig.
6F; Supplemental Fig. S14A). Of note, the effects on ex-
pression levels of IL-6 appeared in the early phase of treat-
ment, while reduction in cell proliferation was evident
after 3 d of treatment (Supplemental Fig. S14E), possibly
due to the kinetics of dampening IL-6 autocrine pathway
signaling. Taken together, these results suggest that
EGFRvIII regulates NF-κB activity and cytokine produc-
tion through the AKT pathway.
Survivin expression in GBM patients
Last, to confirm that the NF-κB/survivin axis is active in
human GBM clinical samples, we examined the phos-
phorylation levels of the p65NF-κB subunit (as a surrogate
Figure 6. PI3K/AKT signaling controls IL-6 secretion in EGFRvIII cells. (A) Schematic representation of Tyr-to-Phe substitutions in
EGFRvIII DY mutants. (B) Bio-Plex analysis for IL-6 in DY mutants. (C ) Western blot analysis of intracellular pathways in DY mutants.
(D,E) NF-κB response element reporter assay inDYmutants (D) or EGFRvIII cells (E, top panel) treatedwith 0.5 µMMK-2206 or 1 µMTIC-
10 for 48 h. (E,middle panel) IL-6 reporter assay in the presence of AKT inhibitors.Western blotting analysis is shown in the bottom panel
of E. (F ) Survivin real-time PCR analysis in PDX cell lines treated with the same inhibitors as in E. Data are represented as mean ± SD.
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biomarker for pathway activation) and the expression lev-
els of survivin from 105 GBM tumors arrayed on a tissue
microarray (Fig. 7A; Tanaka et al. 2011), which showed
that increased phosphorylation of p65 was tightly associ-
ated with high expression of survivin (Fig. 7A,B). More-
over, analysis of TCGA data revealed that BIRC5 is
elevated in glioma patients when compared with normal
brains (P = 2.45 × 10−4, Wilcoxon test) (Fig. 7C). Addition-
ally, gene set enrichment analysis (GSEA) of the transcrip-
tomes of TCGApatients indicated significant correlations
between BIRC5 expression and cell cycle regulation, apo-
ptosis, and NF-κB signaling pathways (Supplemental Fig.
S15A). Erlotinib-treated patients also show a tendency
for increased BIRC5 expression (Supplemental Fig. S15B,
C), similar to our results on acquired resistance in
Ink4a/Arf−/−-EGFRvIII mouse astrocytes (Supplemental
Fig. S7D,E). Taken together, our results show that the
NF-κB/survivin axis is active in human GBM and repre-
sents a valuable target for combinatorial treatment to in-
crease the efficacy of EGFR-directed TKIs.
Discussion
A number of factors contribute to make GBM one the
most challenging cancers to treat. An ideal candidate
drug is one that is capable of crossing the blood–brain bar-
rier, selective in inducing cell death in cancer cells, and
well tolerated by patients. The current standard of treat-
ment entails a maximal surgical resection followed by
DNA-damaging radiotherapy and concomitant temozolo-
mide administration. While the complex genetics of un-
treated GBM are being investigated with next-generation
sequencing technologies (Brennan et al. 2013), it is now
understood that the genetics and epigenetics of gliomas
are also impacted by therapy and tumor progression (John-
son et al. 2014; Mazor et al. 2015; Wang et al. 2016). In
addition to genetics, a central aspect of the pathogenesis
of GBM is its heterogeneity, which is reflected in the
various histological subtypes, epigenetic and gene expres-
sion landscapes, and different cells of origin and tumor
microenvironment constituents, all contributing to the
therapeutically recalcitrant nature of this tumor type
(Alcantara Llaguno et al. 2015; Archetti et al. 2015; Fur-
nari et al. 2015; Caiado et al. 2016; Mazor et al. 2016).
To achieve treatment success for GBM patients, it is crit-
ical to understand the contribution of each one of these tu-
mor features. The EGFR is often amplified and/ormutated
inGBM,with EGFRvIII being a commonmutant that con-
fers a particularly aggressive phenotype to the tumor (Inda
et al. 2010; Furnari et al. 2015). Four subtypes (classical,
mesenchymal, neural, and proneural) of GBM have been
identified by an integrated genomic analysis of human gli-
oma samples, with EGFR initially thought to be a promi-
nent feature of the classical subtype (Verhaak et al. 2010).
The complex interactive nature of wtEGFR/EGFRvIII
characterizes GBM (Inda et al. 2010; Fan et al. 2013;
Nathanson et al. 2014; Furnari et al. 2015; Jahani-Asl
et al. 2016), which we sought to understand here to im-
prove the efficacy of anti-EGFR therapy.
Historically, targeting EGFR has resulted in substantial
therapeutic improvement for lung, breast, and colon can-
cer patients (Scaltriti and Baselga 2006); however, identi-
cal therapies have provided little clinical benefit for
GBM patients (Reardon et al. 2014). Mechanisms of resis-
tance to anti-EGFR therapy also arise in other cancers.
Upon initial response, KRAS mutations nullify anti-
EGFR therapy in colon cancer (Diaz et al. 2012), while
the T790M EGFR mutation alters response to gefitinib
in non-small-cell lung cancer (NSCLC) (Lynch et al.
2004). A major molecular determinant promoting lack of
response to EGFR inhibition is deletion or mutation of
the PTENgene (Mellinghoff et al. 2005). Additionalmech-
anisms are likely to take part in this cell-intrinsic resis-
tance to anti-EGFR treatment (Nathanson et al. 2014;
Reardon et al. 2014; Wykosky et al. 2015). So far, insuffi-
cient attention has been paid to the role of heterogeneity
of EGFR expression in GBM in determining the respon-
siveness to targeted therapy. This study demonstrates
the presence of a wtEGFR/EGFRvIII circuit that conveys
an EGFR TKI resistance mechanism mediated by IL-6.
IL-6 is a pleiotropic factor that is recognized as a molecule
linking inflammation and cancer and is involved in many
solid tumors, such as brain, liver, and colon cancers. It ac-
tivates an immune response within the tumor burden
while simultaneously fueling cancer cells with prosur-
vival signaling (Hodge et al. 2005). In mutationally acti-
vated EGFR-driven NSCLCs, treatment with EGFR TKIs
results in IL-6-mediated feedback activation of STAT3
and downstream prosurvival genes that attenuate drug
sensitivity (Lee et al. 2014). It is interesting to note that,
although NSCLC and GBM, as shown here, use IL-6 as a
cytokine mediator to attenuate EGFR TKI sensitivity,
our study shows that STAT3 is not the critical driver of
this mechanism in GBM but requires theNF-κB transcrip-
tion factor, perhaps illustrating cell type or mutant recep-
tor-specific contextual differences in pathway signaling
(Huang et al. 2009).
We reported previously that EGFRvIII prompted the
growth of wtEGFR+ cells through activation of the IL-
6R/gp130 receptors (Inda et al. 2010). In addition to this
enhanced tumorigenicity, we show here that IL-6 in-
creased NF-κB activation and survivin expression, result-
ing in an anti-apoptotic phenotype. Fostered by IL-6,
wtEGFR+ cells lost their potential to respond to inhibition
by different EGFR TKIs (gefitinib, erlotinib, and lapatinib)
(Fig. 7E; Vivanco et al. 2012). Survivin is part of the inhib-
itor of apoptosis protein (IAP) family, containing a single
baculovirus IAP repeat (BIR) domain. It has broad anti-ap-
optotic action compromising both caspase-dependent and
caspase-independent cell death. It is unaltered in normal
human tissues and up-regulated in malignant transforma-
tion, accounting for the interest in its anti-apoptotic role
in human cancers (Altieri 2008). The small molecule
YM-155 is a reported survivin inhibitor, but a lack in brain
penetrance makes it an unlikely drug for GBM patients
(Minematsu et al. 2012). In this research, we reported
that survivin expression is regulated by NF-κB. NF-κB is
a family of transcription factors comprising NF-κB1
(p105/p50), NF-κB2 (p100/p52), RELA (p65), RELB, and
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Figure 7. The NF-κB/survivin axis is hyperactive in clinical GBM samples. (A) Immunohistochemical images of phospho-p65 and sur-
vivin. Tissue microarray samples are stained with H&E. (B) Immunohistochemical analysis of tissue microarray samples shows statisti-
cally significant correlation (Fisher’s exact test) between phospho-p65 and survivin expression. (C ) TCGA analysis of survivin expression
in GBM versus normal brains. (D) Schematic representation of pathways activation. Intracellular signaling activationmediated by EGFR-
vIII or extracellular activation of the wtEGFR/gp130 complex converges upon activation of NF-κB. Upon TKI-mediated inactivation of
EGFR, IL-6 activation of gp130 promotes cell survival through mTORC2/NF-κB signaling. (E) Interclonal communication of EGFR-ex-
pressing cells results in an apoptosis-resistant phenotype. Tumor cells regain sensitivity to EGFR TKIs through inhibition of NF-κB by
BET bromodomain inhibitors.
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c-Rel. In the canonical pathway of NF-κB activation, di-
mers of NF-κB are kept inactive by the cytosolic inhibitor
IκB. When IκB is targeted for proteasomal degradation by
phosphorylation, active NF-κB migrates to the nucleus
and activates the transcription of genes involved in cancer
progression and chemoresistance; for example, Bcl-2, Bcl-
xl, Cox2, IAP, and CCND1. A variety of stimuli can acti-
vate NF-κB-mediated transcription, among which
wtEGFR and EGFRvIII have been reported to activate
NF-κB (Dan et al. 2008; Tanaka et al. 2011; Cahill et al.
2016). In this regard, NF-κB has been shown to be a major
molecular driver of chemotherapy and radiotherapy resis-
tance in GBM (Tanaka et al. 2011; Bhat et al. 2013; Cahill
et al. 2016; Friedmann-Morvinski et al. 2016). To inhibit
survivin expression, we chose the epigenetic regulator
JQ1, which targets the bromodomain-containing factor
BRD4, known to maintain NF-κB in an active state and
regulate the enhancer-mediated function of this transcrip-
tion factor (Brown et al. 2014; Zou et al. 2014). Moreover,
JQ1 has been shown to abrogate an EGFRvIII-induced
transcriptional regulatory network (Liu et al. 2015). In
our study, JQ1 was indeed able to abrogate both IL-6-me-
diated EGFR TKI resistance and IL-6-induced gefitinib
resistance by restoring induction of cell death mediated
by receptor blockade in both wtEGFR and EGFRvIII cells.
Importantly, we show that JQ1 crosses the blood–brain
barrier, highlighting brain penetrance as an important
consideration in GBM drug development.
In this heterogeneous scenario of cellular cross-talk be-
tween wtEGFR+ and EGFRvIII+ cells, NF-κB serves as a
convergence signaling molecule shared between both
cell types. Indeed, NF-κB activity is stimulated by EGFR-
vIII in EGFRvIII+ cells and from cytokine receptors in
wtEGFR+ cells (Fig. 7D). EGFRvIII is not the only driver
sustaining tumor fitness within the pathologicalmicroen-
vironment. Through its activity, we speculate that EGFR-
vIII can stimulate other cell components of the tumor,
such as microglia, which can similarly secrete IL-6, thus
enhancing the oncogenic effects initiated by EGFRvIII.
By targeting NF-κB, we could potentially eradicate not
just one cell population but all cells responding to the
EGFRvIII stimuli in a heterogeneous environment as pre-
sented in GBM (Fig. 7E; Charles et al. 2011).
Deletion of the NF-κB inhibitorNFKBIA and genetic al-
terations of EGFR are mutually exclusive in GBM (Bredel
et al. 2011)—data that support an essential role for theNF-
κB signaling axis in these tumors.WithwtEGFR/EGFRvIII
being activators of NF-κB, the concomitant inhibition of
both might be therapeutically relevant for GBM patients.
In agreement with our study, application of combined
lapatinib and JQ1 treatment has proven efficacious in a
model of lapatinib-resistant breast cancer, where JQ1
overcomes resistance that is mediated by activation of ad-
ditional receptor tyrosine kinases (Stuhlmiller et al. 2015).
It is likely that multiple inherent and induced molecu-
lar mechanisms contribute to EGFR therapy resistance.
Recent data implicated EGFR amplification andmutation
as initial events in the pathogenesis of GBM, suggesting
that anti-EGFR treatments might be effective as an early
therapeutic intervention (Wang et al. 2016). The emerging
evidence of numerous EGFR variants in GBM, a mixture
of point mutations and minor and major deletions involv-
ing both the extracellular and intracellular domains of the
receptor, presents a variegated receptor landscape with a
unique possibility for intervention once functional/
operational malignant networks are identified and then
uncoupled. More broadly, the consequences of tumor het-
erogeneity—of which EGFR mutation and amplification
represent a microcosm of the full spectrum of GBM het-
erogeneity—are now starting to be understood. Imple-
mentation of the knowledge gained from the study of
the genetic, epigenetic, and microenvironmental factors
cooperating in the formation of a complex tumor land-
scape will ultimately dictate the direction of future ther-
apeutic approaches for GBM patients.
Materials and methods
Cell lines, plasmids, and reagents





U178MG, U178EGFRvIII, U178wtEGFR, U373MG, U373EGFR-
vIII, U373wtEGFR, and U373EGFRvIIITEToff were obtained and
cultured as described previously (Inda et al. 2010; Wykosky et al.
2015). PDX sphere lines were cultured in DMEM/F12 medium
supplemented with B27 (GIBCO/Life Technologies) and 20 ng/
mL human recombinant EGF, 20 ng/mL bFGF, and 2mg/mL hep-
arin (Stem Cell Technologies). GBM6, GBM8, and GBM39 were
provided by David James (Northwestern University); GSC11
and GSC23 were provided by Frederick Lang (M.D. Anderson
Cancer Center); TS543 and TS576 were provided by Cameron
Brennan (Memorial Sloan Kettering Cancer Center); and HK296
was provided by Harley Kornblum (University of California at
Los Angeles). All cells were incubated at 37°C, 5% CO2, and
100% relative humidity in low-attachment flasks. PDX cell lines
were dissociated with Accutase (Stemcell Technologies). EGFR
TKIs (gefitinib, erlotinib, and lapatinib) were purchased from
LC Laboratories, 1-NA-PP1 was from D-L Chiral Chemicals,
and JQ1 was from MedChem Express. All other compounds
were from Selleck Chemicals.
The near-infrared fluorescent protein iRFP720 cDNA con-
struct was from Shcherbakova and Verkhusha (2013), EGFR-
vIIIAS3 was from Fan et al. (2013), and pLV-IκB-SR vector was a
gift from Inder Verma (Salk Institute). shRNA constructs target-
ing survivin, IL-6, IL-8, andGFPwere purchased fromSigma (Mis-
sion shRNA). pLV-EF1a-GFP-IRES-Hyg plasmid (Biosettia) was
used to subclone wtEGFR for sphere transduction. Survivin over-
expression in U87wtEGFR cells was achieved by subcloning sur-
vivin cDNA into the pBABE-puro backbone. The pGL4.32[luc2P/
NF-κB-RE/Hygro] vector for NF-κB luciferase reporter assays was
purchased from Promega. The LightSwitch luciferase assay sys-
tem (Active Motif) was used to analyze IL-6 and the survivin
promoter.
Intracranial injection and tumor size measurement
A total of 2.5 × 105 cells in a 5-µL volumewas injected intracrani-
ally into 4- to 5-wk-old athymic nude mice using a stereotactic
system. Tumors were allowed to establish for 1 wk before any
treatment, and engraftment of tumors was quantitatively con-
firmed via FMT signal intensity at the onset of neurological
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symptoms in the control groups. Tumor growth was monitored
using the FMT 2500 fluorescence tomography system (Perkin-
Elmer). For drug treatment studies, vehicle (20% captisol; A Li-
gand Technology) or 100 mg/kg JQ1 or 200 mg/kg EGFR TKI
gefitinib or lapatinib (LC Laboratories) resuspended in vehicle
was administered once daily to mice via oral gavage starting at
day 7 after injection. 1-NA-PP1 (10mg/kg) was resuspended in ve-
hicle (20%:20%:60% [v/v/v] solutol/PEG400/water) and admin-
istered twice daily by intraperitoneal injection. Mice were
euthanized in accordance with our institutional guidelines for
animal welfare and experimental conduct at University of Cali-
fornia at San Diego. Survival until the onset of neurologic symp-
toms was used for intracranial injections.
Pharmacokinetic studies
Pharmacokinetic studies were conducted by WuXi AppTec with
animals obtained from an approved vendor (Shanghai Laboratory
Animal Co., Ltd. [SLAC]). Compounds in the formulations spec-
ified above were administered by either single intraperitoneal in-
jection (1-NA-PP1) or oral gavage (JQ1) to animals following the
standard operating procedures of the WuXi Apptec animal facili-
ty. 1-NA-PP1 and JQ1 dose levels were 10 mg/kg and 50 mg/kg,
respectively. The dose volume of each animal was determined
by the body weights of animals collected on the dosing day. Sam-
ples were collected from the blood and brains. For blood, bleeding
(∼30 µL of blood per time point) was collected via the submandib-
ular or saphenous vein. All blood samples were transferred into
microcentrifuge tubes containing 4 µL of 0.5 M K2EDTA as an
anti-coagulant and placed on wet ice. Samples were then pro-
cessed for plasma by centrifugation at 3000g for 15 min at 4°C
within 30 min of collection. Plasma samples were stored in poly-
propylene tubes, quick-frozen over dry ice, and kept at −70°C un-
til liquid chromatography/mass spectrometry (LC/MS) analysis.
For brains, whole brains were dissected at the designated time
points after blood samples were collected. The whole-brain sam-
ples were blotted on filter paper, weighed, and then homogenized
in 4 vol of water with a Polytron on ice. The homogenates were
placed on dry ice until LC/MS analysis.
Tissue microarray
The tissue microarray was purchased from US Biomax and im-
munohistochemically stained as described previously (Tanaka
et al. 2011). Briefly, a tissue array consisting of cores from forma-
lin-fixed paraffin-embedded tumors and normal brain blocks was
deparaffinized by immersion in 0.01M citrate buffer (pH 6) for 30
min in a pressure cooker to promote antigen retrieval. Peroxidase
activity was quenched with 3% hydrogen peroxide in water, and
primary antibodies were applied for 16 h at 4°C followed by bio-
tinylated secondary antibodies and the avidin–biotin complex.
Primary antibodies against survivin and phospho-p65 (Cell Sig-
naling Technologies) were used. Negative control slides received
normalmouse serum (Dako) for the primary antibody step. Slides
were counterstained with Harris hematoxylin. Staining intensity
was scored independently by two neuropathologists based on a
scale of three categories indicated as low for negatively stained
specimens, medium for weakly positive samples, and high for
strongly positive spots. Statistical significance between normal
and tumor staining was calculated using the independent t-test.
Statistical analyses were performedwith the two-tailed Student’s
t-test to determine the statistical significance between indepen-
dent samples, with P-values of <0.05 considered statistically
significant.
Gene expression analysis
Normalized gene expression levels (RNA sequencing) for 20,502
genes and clinical information for 160 GBMs and five normal
brains were downloaded from TCGA data portal (https://tcga-
data.nci.nih.gov). Differences in expression levels between tu-
mors treated (n = 4) and not treated (n = 156) with erlotinib were
assessed usingWilcoxon test. Bootstrappingwas performed by se-
lecting four randomBIRC5 expression values between the 156 tu-
mors not treated with erlotinib 100,000 times. Mean expression
valuewas determined for each step, and the P-valuewas calculat-
ed as the number of times that the observed mean BIRC5 expres-
sion value was greater than the randommean expression, divided
by 100,000. Bootstrapping was performed using the samemethod
also on 400 GBMs (18 treated with erlotinib) from TCGA whose
expression levels were measured by microarrays.
Transcriptomal profiling analysis
TCGA GBM transcriptomal profiles were downloaded from
TCGA data portal (http://tcga-data.nci.nih.gov/tcga). Level 3
normalized Agilent 244K gene expression mRNA array data
were downloaded, and genes were median-centered. Correlative
analyses between gene expression were performed using Prism
(GraphPad).
GSEA
The correlation between BIRC5 and each of the other 20,501 hu-
man genes was calculated considering all 160 GBM samples.
Genes ranked from the highest correlation to the lowest correla-
tion were used as input for GSEA (Subramanian et al. 2005). Two-
thousand-one-hundred-fifteen gene sets from the Molecular Sig-
nature Database (MSigDB) (Subramanian et al. 2005), including
50 hallmark (Liberzon et al. 2015), 149 Biocarta (http://www.
biocarta.com), 178 Kyoto Encyclopedia of Genes and Genomes
(KEGG) (Kanehisa et al. 2016), and 512 reactome (Fabregat et al.
2016) gene sets, were analyzed and used as input to run GSEA
with default parameters (1000 permutations and gene set size be-
tween 15 and 500 genes).
Statistical analysis
Experimental datawere from three biological replicates. Data sets
were analyzed by unpaired Student’s t-test or multiple compari-
sons one-way ANOVA or two-way ANOVA according to the ex-
periment using GraphPad Prism software. In all figures, a single
asterisk indicates P < 0.05, double asterisks indicate P < 0.001,
and triple asterisks indicate P < 0.0001. Significancewas conclud-
ed at P < 0.05. Kaplan-Meier curves and comparisons of survival
were analyzed using log-rank (Mantel-Cox) and Gehan-Breslow-
Wilcoxon tests.
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